23 completed. 23 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 23 |
| Phase 2 | 5 | Completed 5 |
Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) LYT-200, Venetoclax, Azacitidine - AML, Adult Recurrent, MDS | Phase 1 | Completed | PureTech | 101 | 2022-12-12 | 2026-05-06 |
| Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS DVX201 - AML, Adult Recurrent, MDS | Phase 1 | Completed | Coeptis Therapeutics | 8 | 2021-12-15 | 2024-07-19 |
| A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) SHR-1702 - AML, MDS | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 31 | 2020-09-10 | 2023-08-24 |
| Haplo Peripheral Blood Sct In GVHD Prevention FLUDARABINE, CYCLOPHOSPHAMIDE, TBI - GVHD, AML | Phase 1 | Completed | Zachariah Michael DeFilipp | 25 | 2020-08-14 | 2025-07-20 |
| CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS CYC065, Venetoclax - AML, MDS | Phase 1 | Completed | Cyclacel Pharmaceuticals, Inc. | 14 | 2019-08-02 | 2024-09-19 |
| DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 NKR-2 - AML, MDS | Phase 1 / Phase 2 | Completed | Celyad Oncology SA | 21 | 2018-09-18 | 2021-05-04 |
| Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS Pevonedistat, Cytarabine - Acute Myelogenous Leukemia, AML | Phase 1 | Completed | Justin Watts, MD | 12 | 2018-05-21 | 2021-12-28 |
| CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia CX-01, Azacitidine, Bone marrow biopsy - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 1 | Completed | Washington University School of Medicine | 20 | 2017-04-07 | 2019-12-05 |
| Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source Fludarabine, Cyclophosphamide, Mesna - Leukemia, MDS | Phase 1 | Completed | Rafic Farah, MD | 28 | 2015-02-11 | 2019-10-15 |
| A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients Azacitidine and LDE255 - MDS | Phase 1 | Completed | Groupe Francophone des Myelodysplasies | 23 | 2015-02-10 | 2018-12-06 |
| Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination - Myelodysplastic Syndrome, MDS | Phase 1 / Phase 2 | Completed | Astex Pharmaceuticals, Inc. | 130 | 2014-10-28 | 2024-08-27 |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation CliniMACS CD34 selection system, ULD IL-2 - Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML) | Phase 1 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 24 | 2014-08-26 | 2018-07-05 |
| Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies FF-10501-01 - AML, CMML | Phase 1 / Phase 2 | Completed | Fujifilm Pharmaceuticals U.S.A., Inc. | 55 | 2014-07-01 | 2025-03-19 |
| Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML) Decitabine, Cytarabine, aclacinomycin - MDS, AML | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 29 | 2012-11-01 | 2016-02-25 |
| SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Guadecitabine - MDS, CMML | Phase 1 / Phase 2 | Completed | Astex Pharmaceuticals, Inc. | 414 | 2011-01-04 | 2025-01-23 |
| Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies TG02 citrate, Carfilzomib, Dexamethasone - AML, ALL | Phase 1 | Completed | Tragara Pharmaceuticals, Inc. | 120 | 2010-08-01 | 2016-05-06 |
| STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders STA-9090 (ganetespib) - AML, CML | Phase 1 | Completed | Synta Pharmaceuticals Corp. | 31 | 2009-03-01 | 2014-09-18 |
| Umbilical Cord Blood Transplant for Hematological Malignancies Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells, Observation Arm - CML, AML | Phase 1 | Completed | University of Pennsylvania | 5 | 2009-01-01 | 2016-08-19 |
| Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function azacitidine - MDS, AML | Phase 1 | Completed | Celgene | 31 | 2008-11-01 | 2019-11-19 |
| Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107) - AML, CML | Phase 1 | Completed | Cytheris, Inc. | 12 | 2008-03-01 | 2012-07-26 |
Showing 20 of 23. Sign in to see all of them.
Leukemia, Myeloid, Acute (9) · Myelodysplastic Syndromes (7) · Recurrence (4) · Hodgkin Disease (3) · Leukemia (3) · Multiple Myeloma (3) · Graft vs Host Disease (2) · Hematologic Neoplasms (2) · Leukemia, Myelomonocytic, Chronic (2) · Lymphoma, Non-Hodgkin (2) · Myeloproliferative Disorders (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Primary Myelofibrosis (2) · Anemia, Aplastic (1) · Aortic aneurysm, familial thoracic 4 (1)
Hematologic Diseases (18) · Hemic and Lymphatic Diseases (18) · Neoplasms (16) · Neoplasms by Histologic Type (14) · Bone Marrow Diseases (12) · Leukemia, Myeloid (10) · Leukemia (9) · Disease Attributes (8) · Immune System Diseases (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Immunoproliferative Disorders (6) · Lymphoproliferative Disorders (6) · Lymphatic Diseases (5) · Chronic Disease (4)
Azacitidine (4) · Cyclophosphamide (3) · Decitabine (3) · fludarabine (3) · Cytarabine (2) · Granulocyte Colony-Stimulating Factor (2) · Mycophenolic Acid (2) · fludarabine phosphate (2) · venetoclax (2) · CYC065 (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Filgrastim (1) · Interleukin-7 (1) · Melphalan (1)
Astex Pharmaceuticals, Inc. (2) · Celgene (1) · Celyad Oncology SA (1) · Chinese PLA General Hospital (1) · Coeptis Therapeutics (1) · Cyclacel Pharmaceuticals, Inc. (1) · Cytheris, Inc. (1) · Daiichi Sankyo (1) · Fujifilm Pharmaceuticals U.S.A., Inc. (1) · Groupe Francophone des Myelodysplasies (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Joanne Kurtzberg, MD (1) · Justin Watts, MD (1) · M.D. Anderson Cancer Center (1) · National Heart, Lung, and Blood Institute (NHLBI) (1)
United States (20) · Canada (2) · China (2) · Belgium (1) · France (1) · Georgia (1)
Aleksandra Filipovic, MD, PhD. (1) · David A Rizzieri, MD (1) · David Porter, MD (1) · Elizabeth Hexner, MD (1) · Frederic Lehmann, MD (1) · Gautam Borthakur, MD (1) · Guillermo Garcia-Manero, MD (1) · James Lowder, MD (1) · Jay Backstrom, MD (1) · Joanne Kurtzberg, MD (1) · Jorge E. Cortes, MD (1) · Justin Watts, MD (1) · Li Yu, M.D. Ph.D. (1) · Marcel van den Brink, MD, PhD (1)
PMID 23012326, PMID 24002496, PMID 26296954, PMID 26858124, PMID 28881839, PMID 30926081, PMID 31060979, PMID 31331399, PMID 32264726, PMID 32285126, PMID 32645016